Homocystinuria a rare cause of low BMD in young patients: A case report with literature review

Homocystinuria a rare cause of low BMD in young patients: A case report with literature review

Abdul-Wahab Al-Allaf, Theresa Paul, Basem Awadh

Rheumatology Section, Department of Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, POBOX 3050,Qatar

International-Journal-of-Case-Reports-2d code

Background: Homocystinuira is a rare autosomal recessive disorder in the metabolism of sulfur-containing amino acid caused by mutations in the cystathionine beta-synthase gene which encodes the pyridoxine (Vitamin B6) dependent enzyme cystathionine beta-synthase. It is characterized by significant elevations in plasma and urine homocysteine concentrations, which could be associated with increased risk of fracture.

Methods: We describe a case of Homocystinuria who suffered from a low impact patellar fracture with a literature review to highlight the critical relationship between homocysteine level and bone health.

Results: We reported a 36-year-old female with a diagnosis of Homocystinuria due to pyridoxine (B6) unresponsive severe Cystathionine Beta-Synthase deficiency. After a minor knee injury she developed a right patellar fracture and her X-ray revealed osteopenia. On examination, she has severe scoliosis in the spine with bilateral aphakia (absence of the lens of the eye). Her labs showed, persistent high Homocysteine above 100 umol/L, Methionine: 383 umol/L (10-42), Vitamin D 12 ng/ml. Her spine X-ray revealed very severe scoliosis with osteopenia but no vertebra fracture. Her DXA scan showed her Z-Score was within the expected range for her age in hip, spine and 1/3 radius areas, however her ultra-distal radius Z-Score was -4.0. Her Homocystine level was mostly higher than 100 due to non-compliance with dietary advice and treatment. High homocysteine levels in Homocystinuric patients impair the function of bone cells that regulate bone remodeling as well as bone material properties such as collagen cross-linking. This imbalance between bone formation and resorption may lead to a low BMD and fracture in patients with homocystinuria. Interestingly, even in general population hyperhomocystinemia with a plasma level of more than > 13 nmol/ml has been found to be associated with low BMD and an increased risk of fractures that is independent of BMD. Deficiencies in vitamin B6, B12, or folate can lead to increased serum levels of Homocysteine as these vitamins act as co-factors for various enzymes involved in homocysteine metabolism. This can be easily rectified with dietary intervention.

Conclusion: In young patients with a fracture or low bone mineral density, hyperhomocystinemia could play an important role in the pathogenesis. This should be included in the work up for secondary causes for osteoporosis for this age-group. Simple dietary measures and vitamin B6, folate and B12 supplement should be considered as adjuvant therapeutic option for any patient with osteoporosis and fractures, if deficient. Possibly the BMD of the ultra-distal radius is the most sensitive to detect bone changes in these patients.

Keywords: Homocystinuria, low BMD, young patients

Free Full-text PDF

How to cite this article:

Abdul-Wahab Al-Allaf, Theresa Paul, Basem Awadh. Homocystinuria a rare cause of low BMD in young patients: A case report with literature review. International Journal of Case Reports, 2020 4:133. DOI: 10.28933/ijcr-2020-05-1305


1. Picker, JD.; Levy, HL. Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. In: Pagon, RA.; Adam, MP.; Ardinger, HH.; Wallace, SE.; Amemiya, A.; Bean, LJH.; Bird, TD.; Fong, CT.; Mefford, HC.; Smith, RJH.; Stephens, K., editors. GeneReviews(R). University of Washington; Seattle, Seattle WA: 2004. last updated 2014 Nov 13.
2. Robert R. McLean, M.P.H., Paul F. Jacques, D.Sc., Jacob Selhub, Ph.D., Katherine L. Tucker, Ph.D., Elizabeth J. Samelson, Ph.D., Kerry E. Broe, M.P.H., Marian T. Hannan, D.Sc., L. Adrienne Cupples, Ph.D., and Douglas P. Kiel, M.D Homocysteine as a Predictive for Hip Fracture in Older Persons. New England Journal of Medicine 350 :20 May 13, 2004;2042-2049.
3. Van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350(20):2033.
4. Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Väänänen HK, Obrant KJ, Akesson K. Associations between Homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res. 2007;22(1):127.
5. Yang J, Hu X, Zhang Q, et al. Homocysteine level and risk of fracture: a meta-analysis and systematic review. Bone. 2012;51: 376–382.
6. Brenton DP. Skeletal abnormalities in Homocystinuria. Postgrad Med J. 1977; 53:488–496. PubMed: 917963
7. Brill PW, Mitty HA, Gaull GE. Homocystinuria due to cystathionine synthase deficiency: clinical- roentgenologic correlations. Am J Roentgenol Radium Ther Nucl Med. 1974; 121:45–54.
8. Gaudier B, Remy J, Nuyts JP, Caron-Poitreau C, Bombart E, Foissac-Gegoux MC. Radiologic study of the osseous symptoms of Homocystinuria. (6 cases). Arch Fr Pediatr. 1969; 26:963–975. PubMed: 5371368
9. 9. MacCarthy JM, Carey MC. Bone changes in Homocystinuria. Clin Radiol. 1968; 19:128–134. PubMed: 5648071
10. Schedewie H, Willich E, Grobe H, Schmidt H, Muller KM. Skeletal fingings in Homocystinuria: a collaborative study. Pediatr Radiol. 1973; 1:12–23. PubMed: 4768238
11. Shaw DG. Letter: Enlarged epiphyses: megepiphyseal dwarfism or Homocystinuria? J Pediatr. 1974; 85:145. PubMed: 4852777
12. Thomas PS, Carson NA. Homocystinuria. The evolution of skeletal changes in relation to treatment. Ann Radiol (Paris). 1978; 21:95–104. PubMed: 677757
13. Schiff M, Blom HJ. Treatment of inherited homocystinurias. Neuropediatrics. 2012; 43:295–304. PubMed: 23124942
14. Adam S, Almeida MF, Carbasius Weber E, Champion H, Chan H, Daly A, Dixon M, Dokoupil K, Egli D, Evans S, Eyskens F, Faria A, Ferguson C, Hallam P, Heddrich-Ellerbrok M, Jacobs J, Jankowski C, Lachmann R, Lilje R, Link R, Lowry S, Luyten K, MacDonald A, Maritz C, Martins E, Meyer U, Muller E, Murphy E, Robertson LV, Rocha JC, Saruggia I, Schick P, Stafford J, Stoelen L, Terry A, Thom R, van den Hurk T, van Rijn M, van Teefelen-Heithoff A, Webster D, White FJ, Wildgoose J, Zweers H. Dietary practices in pyridoxine non-responsive Homocystinuria: a European survey. Mol Genet Metab. 2013; 110:454–459. PubMed: 24206934
15. Finkelstein, J. D. (1990). Methionine metabolism in mammals. Journal of Nutritional Biochemistry, 1, 228–237.
16. Lim JS, Lee DH. Changes in bone mineral density and body com- position of children with well-controlled Homocystinuria caused by CBS deficiency. Osteoporosis Int. 2013 Sep;24 (9):2535–2538.
17. Smith, S. W. (1967). Roentgen findings in Homocystinuria. American Jour- nal of Roentgenology, Radium Therapy, and Nuclear Medicine, 100(1), 147– 154
18. Mudd, S. H., Levy, H. L., & Kraus, J. P. (2001). Disorders of transsulfuration. In C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle, B. Childs, K. Kinzler, & B. Vogelstein (Eds.), The Metabolic and Molecular Bases of Inherited Disease (pp. 2007–2056). New York: McGraw-Hill.
19. Schedewie, H., Willich, E., Grobe, H., Schmidt, H., & Muller, K. M. (1973). Skeletal fingings in Homocystinuria: A collaborative study. Pediatric Radi- ology, 1(1), 12–23.
20. Parrot, F., Redonnet-Vernhet, I., Lacombe, D., & Gin, H. (2000). Osteoporosis in late-diagnosed adult omocystinuric patients. Journal of Inherited Metabolic Disease, 23(4), 338–340.
21. Milovanovic P, Hrncic D, Radotic K, Stankovic M, Mutavdzic D, Djonic D, et al. Moderate Hyperhomocysteinemia induced by short- term dietary methionine overload alters bone microarchitecture and collagen features during growth. Life Sci. 2017;191:9–16.
22. Cortese C, Motti C. MTHFR gene polymorphism, Homocysteine and cardiovascular disease. Public Health Nutr. 2001;4:493–497.
23. Vacek TP, Kalani A, Voor MJ, et al. The role of Homocysteine in bone remodelling. Clin Chem Lab Med. 2013;51:579–590.
24. Koh JM, Lee YS, Kim YS, Kim DJ, Kim HH, Park JY, et al. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res. 2006;21:1003–1011.
25. Herrmann M, Widmann T, Colaianni G, et al. Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem. 2005;51:2348–2353.
26. Vaes BL, Lute C, Blom HJ, et al. Vitamin B(12) deficiency stimulate osteoclastogenesis via increased Homocysteine and methylmalonic acid. Calcif Tissue Int. 2009;84:413–422.
27. Kim DJ, Koh JM, Lee O, Kim NJ, Lee YS, Kim YS, et al. Homocysteine enhances Apoptosis in human bone marrow stromal cells. Bone. 2006;39(3):582–590.
28. Cai B, Li X, Wang Y, Liu Y, Yang F, Chen H, et al. Apoptosis of bone marrow mesenchymal stem cells caused by Homocysteine via activating JNK signal. PLoS One. 2013;8:e63561.
29. Lv H, Ma X, Che T, Chen Y. Methylation of the promoter A of estrogen receptor alpha gene in hBMSC and osteoblasts and its correlation with Homocysteine. Mol Cell Biochem. 2011;355:35– 45.
30. Takeno A, Kanazawa I, Tanaka K, Notsu M, Yokomoto M, Yamaguchi T, et al. Activation of AMP-activated protein kinase protects against homocysteine-induced Apoptosis of osteocytic MLO-Y4 cells by regulating the expressions of NADPH oxidase 1 (Nox1) and Nox2. Bone. 2015;77:135–141.
31. Kanazawa I, Tomita T, Miyazaki S, Ozawa E, Yamamoto LA, Sugimoto T. Bazedoxifene ameliorates homocysteine-induced Apoptosis and accumulation of advanced glycation end products by reducing oxidative stress in MC3T3-E1 cells. Calcif Tissue Int. 2017;100:286–297.